- Home
- About
- 🤖 AskAnzal AI Advisor
- 📅 Book a Call
- Your Account
- My AskAnzal Account
Cases selected for the AskAnzal weekly PMCPA insight newsletter
Intercompany complaint about Jext leavepiece diagrams and the claim “designed to be easy to use”. Panel found the…
PMCPA case AUTH/3068/9/18 (Director v Sanofi) concerned clinical trial disclosure but was ruled outwith the scope of the…
Anonymous complaint alleged unsolicited promotional emails to NHS staff about setting up ‘oral chemotherapy’ clinics without consent or…
A chief pharmacist complained about a Cipralex (escitalopram) promotional email sent via a database agency to local prescribers…
Actavis’ Levosert leavepiece implied broader suitability than Mirena and claimed a “25% saving” on acquisition cost. PMCPA ruled…
Public complaint alleged Sanofi failed to disclose clinical trial results for Multaq and Jevtana in line with ABPI/IFPMA…
Anonymous complaint alleged coercive, industry-funded audits/workshops linked to prescribing. Most allegations not proven, but AstraZeneca was found in…
Shield’s corporate site contained publicly accessible promotional content for Feraccru and promotional descriptions of unlicensed pipeline products. PMCPA…
A Versatis budget impact brochure compared “Total NHS cost” vs gabapentin but didn’t clearly define what costs were…
Complaint about omission of prescribing information/obligatory information. PMCPA concluded no breach and that the matter was outwith the…
One real case. One key lesson. Every week — free.